Newsroom
 
           
  Current News
  Press Releases
  Scientific Publications
  Abstracts & Presentations

Scientific Publications


Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism 
Aleong, RG, et. al.
J Am Coll Cardiol: Heart Failure, in press.

Treatment of the Heart Failure Patient with Atrial Fibrillation: A Major Unmet Need 
Michael R. Bristow, MD, PhD; Ryan G. Aleong, MD
JACC: Heart Failure, 2013

Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Chronic Heart Failure
Aleong, RG, et.al.
Circulation: Arrhythmia and Electrophysiology, 2013


Effect of Bucindolol on HF Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction HF and Atrial Fibrillation
Kao, DP, et.al.
European Journal of Heart Failure, 2012

Combinatorial Pharmacogenetic Interactions of Bucindolol and Beta-1, Alpha-2C Adrenergic Receptor Polymorphisms
O’Connor, CM, et. al.
PLOS ONE, 2012

 

Pharmacogenetic Targeting of Drugs for Heart Failure
Bristow, MR, et. al.
Pharmacology & Therapeutics: Elsevier, 2012

 

The Development of Beta-Adrenergic Receptor Antagonists for the Treatment of Heart Failure: A Paradigm for Translational Science
Feldman, AM
Circulation Research, 2011

 

Treatment of Chronic Heart Failure with Beta-Adrenergic Receptor Antagonists: A Convergence of Receptor Pharmacology and Clinical Cardiology
Bristow, MR
Circulation Research, 2011

 

An α2c – Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the β-Blocker Bucindolol in Chronic Heart Failure
Bristow, MR, et. al.
Circulation: Heart Failure, 2010

 

Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)
Tate CW, et. al.
Journal of Cardiac Failure, 2007

 

A Polymorphism Within a Conserved β1-adrenergic Receptor Motif Alters Cardiac Function and β-blocker Response in Human Heart Failure
Liggett S, et. al.
The National Academy of Sciences, 2006

 

Impact of Nonfatal Myocardial Infarction on Outcomes in Patients With Advanced Heart Failure and the Effect of Bucindolol Therapy
O’Connor C, et. al.
The American Journal of Cardiology, 2005

 

Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the Beta-Blocker Evaluation of Survival Trial (BEST)
Bristow M, et. al.
Circulation, 2004

 

β1 – Adrenergic Receptor Polymorphisms Confer Differential Function and Predisposition to Heart Failure
Mialet Perez, et. al.
Nature Medicine, 2003

 

A Comparative Analysis of the Results from 4 Trials of β-Blocker Therapy for Heart Failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS
Domanski M, et. al.
Journal of Cardiac Failure, 2003

 

The Effect of Diabetes on Outcomes of Patients With Advanced Heart Failure in the BEST Trial
Domanski M, et. al.
Journal of the American College of Cardiology, 2003

 

Synergistic Polymorphisms of β1 and α2c – Adrenergic Receptors and the Risk of Congestive Heart Failure
Small, et. al.
New England Journal of Medicine, 2002

 

A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
The BEST Manuscript Writing Committee
New England Journal of Medicine, 2001

 

DISCLAIMER

Bucindolol is currently an investigational compound that has not been approved by the FDA for use in the United States. ARCA biopharma has submitted a new drug application to the FDA for bucindolol. The information on this page is for health care professionals only.
 
ARCA ©2013 ARCA biopharma | Home | Site Map | Legal Disclaimer